Introduction: Industry Confidence Amid Uncertainty
The life sciences industry stands at a critical crossroads as it enters 2026. While the sector continues to expand across global markets, confidence levels reveal a striking paradox. According to Deloitte’s 2026 Life Sciences Outlook Survey, over 75% of biopharma and medtech executives express confidence in their organizations’ financial prospects. However, this internal optimism contrasts sharply with broader economic sentiment—only 41% feel positive about the global economy’s health.
This divergence underscores a fundamental challenge facing industry leaders: navigating organizational success within an uncertain macroeconomic environment. The year ahead demands a delicate balance between bold technological investments and pragmatic adaptation to regulatory and economic shifts.
Success in 2026 will likely belong to organizations that can harmonize global momentum with local resilience, leveraging artificial intelligence and emerging technologies while maintaining agility to respond to regional market dynamics.
Survey Methodology and Scope
To capture comprehensive industry insights, the Deloitte US Center for Health Solutions partnered with Deloitte Global to conduct its fourth annual Life Sciences Outlook Survey between August and September 2025. The research encompassed 280 C-suite executives from biopharma and medtech companies across three major regions:
- United States: North American market leaders
- Europe: Executives from France, Germany, Switzerland, and the United Kingdom
- Asia: Leaders from China and Japan
The survey findings were further enriched through in-depth interviews with several industry leaders, providing qualitative context to the quantitative data. This multi-dimensional approach ensures a holistic understanding of the challenges and opportunities facing the life sciences sector.
Regional Confidence Variations
Biopharma Sector Outlook
Regional differences in confidence levels reveal distinct market dynamics across geographies. In the surveyed European and Asian countries, 90% of biopharma leaders report “positive” or “cautiously positive” expectations for 2026. Remarkably, 83% predict steady or strong revenue growth, with only 2% anticipating decline.
The US market presents a more tempered perspective. Among American biopharma leaders, 56% express positive or cautiously positive outlooks, while 27% remain negative or uncertain about the coming year. Revenue growth expectations reflect this caution: 71% anticipate gains, but 18% foresee decline—a significantly higher pessimism rate than their international counterparts.
Medtech Sector Projections
The medtech sector demonstrates greater optimism across all regions compared to biopharma. A robust 81% of surveyed medtech executives anticipate revenue growth in 2026. Geographic analysis reveals consistent confidence levels, with 84% of US-based medtech leaders and 78% of those outside the United States expecting growth—a difference lacking statistical significance.
This uniformity suggests that medtech companies face a more globally consistent operating environment, potentially benefiting from universal healthcare technology needs and less region-specific regulatory pressures.
Strategic Priorities for Growth
Despite overall optimism, life sciences leaders acknowledge significant headwinds that complicate growth strategies. Persistent geopolitical tensions, pricing pressures, and regulatory shifts demand sophisticated operating models and strategic flexibility.
The traditional US-focused growth strategy is evolving toward a more fragmented global landscape. Companies now carefully evaluate nuanced decisions about product advancement, launch markets, and pricing strategies tailored to regional conditions.
As one European corporate strategy executive observes: “In these times, if you have a diversified footprint, you can build that agility muscle to react without being completely dependent on one thing.”
Gabriele Ricci, Chief Data and Technology Officer at Takeda Pharmaceuticals, offers another perspective: “Volatility fuels innovation. We’re entering a period of purposeful transformation, where discipline and innovation must coexist as the industry matures beyond hype toward measurable productivity from AI and data.”
Key Trends Shaping 2026 Strategies
Growing Regulatory and Policy Influence
Regulation emerged as the most frequently cited trend affecting organizational strategy. Fifty-one percent of non-US respondents highlighted national regulatory changes, including:
- EU AI Act: Governing artificial intelligence deployment
- Corporate Sustainability Reporting Directive: Mandating ESG disclosures
- European Health Data Space: Standardizing health data access
- China’s Volume-Based Procurement Program: Impacting pricing structures
In the United States, 36% cited agency restructuring within the FDA and HHS, while 39% highlighted economic policy changes, including tariffs that could reshape market access and portfolio management decisions.
Acceleration of Digital Transformation and AI
Nearly half of respondents (48%) identified accelerated digital transformation as a substantial 2026 influence—a statistically significant increase from 2025. The proliferation of generative AI (41% of respondents) demonstrates how analytics and automation increasingly shape research, manufacturing, and commercial operations.
Notably, 30% cited agentic AI—autonomous systems capable of independent decision-making—a new survey category signaling growing interest in advanced digital capabilities. However, only 22% of leaders report successfully scaling AI, and just 9% achieve significant returns, revealing an implementation gap.
Cybersecurity concerns accompany this digital acceleration, with 35% identifying it as a strategic factor.
Persistent Pricing and Access Challenges
Pricing and access remain major considerations for 44% of respondents. Additional pressures include:
- Competitive pressure from generics and biosimilars (37%)
- Patent cliffs and blockbuster drug expirations (26%)
- Reimbursement model evolution across markets
Heightened Geopolitical and Economic Uncertainty
Geopolitical tensions have emerged as a critical concern, with 39% naming it a top issue—a 20-percentage-point jump from 2025, representing the largest year-over-year increase. Nearly equal shares (38%) identified inflation, economic pressures, and supply chain risks as strategic factors.
Evolving Customer Models and Needs
One-third of respondents (33%) identified connected care delivery as a top trend—a 15-percentage-point increase. Customer adoption of digital tools (35%) and evolving preferences (32%) highlight the ongoing shift in care delivery models.
As a US medtech supply chain executive notes: “There aren’t enough phlebotomists or lab managers. Our customers don’t have enough people capacity. We need to automate things for them and make it cost-effective.”
Looking Forward: Transformation and Resilience
Industry leaders agree that real transformation in 2026 requires innovative thinking, agile operating models, and robust external partnerships. Organizations must balance bold technological investments with pragmatic responses to regulatory and economic change.
The year ahead rewards those who can harmonize global momentum with local resilience, positioning their organizations for sustained growth amid ongoing uncertainty. Success depends on embracing volatility as a catalyst for innovation while maintaining disciplined execution across all operations.
